Compare Novo Nordisk A/S (NVO) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Abrdn Physical Platinum Shares ETF — how do they compare? Novo Nordisk A/S trades at $46.22 (market cap $207.85B), while Abrdn Physical Platinum Shares ETF trades at $15.95. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals.
| NVO | PPLT | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $25.23 |
52-Week Low | $35.29 | $11.95 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.955, up 0.28% with a bullish technical signal from moving averages, though RSI levels above 74 suggest overbought conditions. The ETF holds physical platinum, benefiting from recent precious metals momentum, but key financial ratios like P/E and P/S are unavailable for this commodity trust. A 1:10 stock split is scheduled for May 26, 2026, which may affect liquidity.
The outlook hinges on platinum catching up to gold and silver rallies, as noted by financial media, but risks include commodity price volatility and zero dividends. Investment appeal lies in potential mean reversion in precious metals ratios, yet investors face exposure to industrial demand fluctuations and macroeconomic factors influencing platinum prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
